Recommendations for the management of COVID 19 patients regarding proarrhythmic effects of some current treatments, specifically if these patients suffer from arrhythmias, and for those receiving antiarrhythmic therapy.

Recommendation provides information to employees of medical departments at any level and primarily primary care about the possible proarrhythmic and adverse effects of drugs used for the treatment of COVID-19 patients and the features of therapy for COVID-19 patients with heart rhythm and conduction disorders receiving permanent antiarrhythmic therapy

coronavirus infection (COVID-19), antiarrhythmic therapy, hydroxychloroquine, QT interval, polymorphic ventricular tachycardia torsades de pointes

1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; [Epub ahead of print]. DOI: 10.1001/jama.2020.6019

2. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;105949. [Epub ahead of print]. DOI: 10.1016/j.ijantimicag.2020.105949

3. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents. 2020;55(4):105932. DOI: 10.1016/j.ijantimicag.2020.105932

4. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. 2020;382(19):1787–99. DOI: 10.1056/NEJMoa2001282

5. Lala A, Johnson KW, Russak AJ, Paranjpe I, Zhao S, Solani S et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection. Cardiovascular Medicine. preprint. DOI: 10.1101/2020.04.20.20072702 [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.04.20.20072702].2020.

6. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;CIRCULATIONAHA.120.047549. [Epub ahead of print]. DOI: 10.1161/CIRCULATIONAHA.120.047549

7. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;e201017. [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1017

8. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T–U Waves Precede Torsades de Pointes in Long QT Syndrome. Journal of the American College of Cardiology. 2009;54(2):143–9. DOI: 10.1016/j.jacc.2009.03.043

9. Kalatsei L.V., Snezhitskiy V.A. Long QT syndrome. Part 2. Journal of the Grodno State Medical University. 2018;16(5):533–41. [Russian: Колоцей Л.В., Снежицкий В.А. Синдром удлиненного интервала QT. Часть 2. Журнал Гродненского государственного медицинского университета. 2018;16(5):533-41]. DOI: 10.25298/2221-8785-2018-16-5-533-541

10. Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram. Journal of the American College of Cardiology. 2009;53(11):982–91. DOI: 10.1016/j.jacc.2008.12.014

11. Kalatsei L.V., Snezhitskiy V.A. Methodological approaches to measuring and estimating the duration of QT interval of a standard electrocardiogram. Journal of the Grodno State Medical University. 2019;17(1):99–105. [Russian: Колоцей Л.В., Снежицкий В.А. Методологические подходы к измерению и оценке длительности интервала QT стандартной электрокардиограммы. Журнал Гродненского государственного медицинского университета. 2019;17(1): 99-105]. DOI: 10.25298/2221-8785-2019-17-1-99-105

12. Liang T. Handbook of COVID-19 Prevention and Treatment. Zhejiang University School of Medicine;2020. - 68 p. [Av. at: http://education.almazovcentre.ru/wp-content/uploads/2020/03/Spravochnik_ po_profilaktike_i_lecheniju_COVID_19.pdf]

13. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clinic Proceedings. 2020;95(6):1213–21. DOI: 10.1016/j.mayocp.2020.03.024

14. Charbit B, Alvarez JC, Dasque E, Abe E, Démolis JL, Funck-Brentano C. Droperidol and Ondansetron-induced QT Interval Prolongation: A Clinical Drug Interaction Study. Anesthesiology. 2008;109(2):206–12. DOI: 10.1097/ALN.0b013e31817fd8c8

15. Hreiche R, Plante I, Drolet B, Morissette P, Turgeon J. Lengthening of Cardiac Repolarization in Isolated Guinea Pigs Hearts by Sequential or Concomitant Administration of Two IKr Blockers. Journal of Pharmaceutical Sciences. 2011;100(6):2469–81. DOI: 10.1002/jps.22437

16. Meid AD, Bighelli I, Mächler S, Mikus G, Carrà G, Castellazzi M et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Therapeutic Advances in Psychopharmacology. 2017;7(12):251–64. DOI: 10.1177/2045125317721662

17. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR et al. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. Circulation: Cardiovascular Quality and Outcomes. 2013;6(4):479–87. DOI: 10.1161/CIRCOUTCOMES.113.000152

18. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; [Epub ahead of print]. DOI: 10.1001/jama.2020.4683

19. Albert RK, Schuller JL. Macrolide Antibiotics and the Risk of Cardiac Arrhythmias. American Journal of Respiratory and Critical Care Medicine. 2014;189(10):1173–80. DOI: 10.1164/rccm.201402-0385CI

20. Cornett E, Novitch MB, Kaye AD, Pann CA, Bangalore HS, Allred G et al. Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review. Postgraduate Medicine. 2017;129(7):715–24. DOI: 10.1080/00325481.2017.1362938

21. Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F. QT Interval Prolongation and Torsades de Pointes Due to a Coadministration of Metronidazole and Amiodarone. Pacing and Clinical Electrophysiology. 2005;28(5):472–3. DOI: 10.1111/j.1540-8159.2005.09348.x

22. Wiener I, Rubin DA, Martinez E, Postman J, Herman MV. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration. The Mount Sinai Journal of Medicine, New York. 1981;48(1):53–5. PMID: 6970886

23. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. Canadian Medical Association Journal. 2011;183(3):303–7. DOI: 10.1503/cmaj.100702

24. Labbe L, Robitaille NM, Lefez C, Potvin D, Gilbert M, O’Hara G et al. Effects of Ciprofloxacin on the Stereoselective Disposition of Mexiletine in Man: Therapeutic Drug Monitoring. 2004;26(5):492–8. DOI: 10.1097/00007691-200410000-00006

25. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Current Medical Research and Opinion. 2013;29(1):1–12. DOI: 10.1185/03007995.2012.747952